PPT-Treatment outcomes with bedaquiline use when substituted for second-line

injectables in multidrug resistant tuberculosis a retrospective cohort study Ying Zhao Tamaryn Fox Kathryn Manning Annemie Stewart Nicki Tiffin Andrew Boulle Vanessa Mudaly . Scott K. . Heysell. MD, MPH. (no disclosures). Why do we need new drugs/ regimens?. ▪Isoniazid and pyrazinamide remain some of the most . toxic. antibiotics prescribed for infectious disease . -. Scott K. . Heysell. MD, MPH. (no disclosures). Why do we need new drugs/ regimens?. ▪Isoniazid and pyrazinamide remain some of the most . toxic. antibiotics prescribed for infectious disease . -. F. uture . of TB . Therapy. Putting science to work for better, faster TB cures. Achieving maximum impact will require:. Short, simple regimens that are adopted, available and affordable.. Ideally, a universal regimen consisting of all novel drugs that is effective in all people with active TB. . Dr Francesca Conradie . Treatment of Drug sensitive TB. 6 months of treatment consisting of . Intensive phase- INH, Rif, PZA and Ethambutol for 2 months. Continuation phase- INH and Rif. Medications are co-formulated. Dr Kaspars Lunte. Team Leader Sourcing and Special Projects, GDF. Copenhagen, IPC . Meeting . 18 June 2015. . Update on GDF Procurement . Change of the hosting agreement from WHO to UNOPS as from January 1 2015. MMed. (. Fam. Med) (MED). Director, . Drug-Resistant TB, TB & HIV . Models of Care for People with Drug-Resistant TB: Advancements in South Africa. Background and TB burden in South Africa. Models . Ramakotaiah Mulamreddy. and William D. Lubell . Département de Chimie, Université de Montréal, Montréal, Canada. Abstract. g. -Substituted Adl analogs were synthesized by effective methods, including constrained Glu-Gly and Gln-Gly dipeptides for mimicry of . 0 2005,DESIDOCStructure-biological Activity Relationship of Analogues of 2-Chlorobenzylidenemalononitrile-A Riot-control AgentP.K. Gutch, Pravin Kumar, M.V.S. Suryanarayana, and R.C. MalhotraDefence WHAT DOES IT MEAN?. 6. 6. 4. 4. 1. 1. x24. x24. one-month or once weekly treatment regimens for . TB prevention. . . four-month treatment regimens for drug-sensitive TB.  . six-month treatment regimens for . a model orography . intercomparison. and implications for drag . parameterization. Andy Elvidge. 1. , Irina Sandu. 2. , Nils Wedi. 2. , . Ayrton. Zadra. 3. , Simon Vosper. 1. , . Masashi Ujiie. 4. , Mikhail Tolstykh. Reaching Zero TB Deaths and Zero New TB Infections. Satellite Symposium, Kuala Lumpur, Malaysia. Dalene and Arne von Delft. 13 November 2012. Dalene von Delft. MB.ChB South Africa, 2006. Completed 2 years internship and 1 year community service, 2007-2009. africa. . Prof. Norbert NDJEKA. MD, DHSM (Wits), . MMed. (Fam Med) (MED), Dip HIV Man (CMSA), DSc (. h.c.. ) (UCT). Chief Director: TB Control & Management. September 14. th. , 2023. BDQ Antibacterial Spectrum. failing second-line therapy . in Malawi. Rachel Kamba. @. TwitterHandle. Share your thoughts on this presentation with . #IAS2019. HIV-1 drug resistance and third-line outcomes among children and adolescents . Anthony Sena. Objectives. Characterize treatment patterns in newly diagnosed RA population from 2000-2018. Compare treatment patterns observed in real-world data to international guidelines (ACR, EULAR).